Skip to main
NVCR
NVCR logo

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 29%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd is positioned for accelerated revenue growth due to new study results that may allow glioblastoma patients to commence treatment 2-3 months earlier, potentially increasing revenue per patient by approximately 20-30%. The expansion of active patients in the U.S. and Germany is anticipated to contribute positively to revenue growth throughout 2026, highlighting a favorable trajectory for the company's financial performance. Additionally, incremental revenue is expected from new markets within the next 12-18 months, bolstering the existing growth drivers for the company.

Bears say

NovoCure Ltd is projected to experience a significant decline in EBITDA as revenue growth is anticipated to be gradual, resulting in a projected breakeven level by 2027. This delay in reaching profitability raises concerns regarding the company's financial viability and overall sustainability. Additionally, the reliance on revenue ramp-up from its existing product lines may pose risks to the company's growth trajectory amidst competitive pressures in the oncology market.

Novocure (NVCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 29% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 7 analysts, Novocure (NVCR) has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.